Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

Pediatric Infectious Disease Journal

Volumn 15, Issue 1, 1996, Pages 23-31

  Piedra, Pedro A ^a   Grace, Susan ^a   Jewell, Alan ^a   Spinelli, Susan ^a   Bunting, Dawn ^a   Hogerman, Deborah A ^b   Malinoski, Frank ^b   Hiatt, Peter W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Lederle Praxis Biologicals   (United States)

Author keywords

cystic fibrosis; purified fusion protein vaccine; Respiratory syncytial virus

Indexed keywords

HYBRID PROTEIN; PLACEBO; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE; LOWER RESPIRATORY TRACT INFECTION; MALE; PAIN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SKIN MANIFESTATION; VACCINATION; VIRUS INFECTION;

CHILD; CHILD NUTRITION PHYSIOLOGY; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; ENVIRONMENT; HN PROTEIN; HUMANS; INFANT; PLACEBOS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SEVERITY OF ILLNESS INDEX; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0030031491     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199601000-00006     Document Type: Article

References (35)

1. McConnochie KM, Hall CB, Walsh EE, Roghmann KJ. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr 1990;117:52-62.
2. McMillan JA, Tristram DA, Weiner LB, Higgins AP, Sand-strom C, Brandon R. Prediction of the duration of hospitalization in patients with respiratory syncytial virus infection: use of clinical parameters. Pediatrics 1988;81:22-6.
3. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
4. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
5. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
6. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-33.
7. Hildreth SW, Baggs RR, Brownstein DG, Castleman WL, Paradiso PR. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization. Vaccine 1993;11:615-8.
8. Wathen MW, Kakuk TJ, Brideau RJ, Hausknecht EC, Cole SL, Zaya RM. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis 1991;163:477-82.
9. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395-404.
10. Kakuk TJ, Soike K, Brideau RJ, et al. A human respiratory syncytial virus (ESV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993;167:553-61.
11. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993;167:191-5.
12. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993;168:1024-9.
13. Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, Paradiso P. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 1994;12:551-6.
14. Petersen NT, Hoiby N, Mordhorst CH, et al. Respiratory infections in cystic fibrosis patients caused by virus, Chlamydia and Mycoplasma: possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand 1981;70:623-8.
15. Wang EEL, Prober CG, Manson B, et al. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984;311:1653-8.
16. Abman SH, Ogle JW, Butler-Simon N, et al. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113:826-30.
17. Hiatt PW, Taber L, Raboud S, Treece D. Respiratory viral infection and pulmonary function in infants with cystic fibrosis [Abstract 115]. Am Rev Respir Dis 1992;145.
18. Hiatt PW, Piedra PA, Raboud S, Treece D. Respiratory viral infection in infants with cystic fibrosis [Abstract 464]. Am Rev Respir Dis 1993;147.
19. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. J Pediatr 1994;124:177-92.
20. Lewiston N, Moss R, Hindi R, Rubinstein S, Sullivan M. Interobserver variance in clinical scoring for cystic fibrosis. Chest 1987;91:878-82.
21. Brasfield D, Hicks G, Soong SJ, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics 1979;63:24-9.
22. Hamill PVV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979;32:607-29.
23. Frisancho AR. New norms of upper limb fat and muscle area for assessment of nutritional status. Am J Clin Nutr 1981;34:2540-5.
24. Piedra PA, Glezen WP, Kasel JA, et al. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 1995;13:1095-1111.
25. Johnson PR, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987;61:3163-6.
26. Walsh EE, Brandriss MW, Schlesinger JJ. Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol 1987;68:2169-76.
27. Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994;125:635-41.
28. Piedra PA, Wyde PR, Castleman WL, et al. Enhance pulmonary pathology associated with the use of formalininactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine 1993;11:1415-23.
29. Hosmer DW Jr, Lemeshow S, eds. In: Applied logistic regression. New York: Wiley, 1989:82-132.
30. Groothuis JR, Simoes EAF, Levin MJ. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
31. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from lowincome families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-15.
32. Kasel JA, Walsh EE, Frank AL, Baxter BD, Taber LH, Glezen WP. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol 1988;1:199-205.
33. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
34. Corey M, Levison H, Crozier D. Five to seven year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis 1976;114:1085-92.
35. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994;169:1368-73.